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ABSTRACT

DEPRESSION IN REPRODUCTIVE-AGE WOMEN:
ASSESSMENT OF INFECTIOUS, ENDOCRINOLOGICAL, AND
IMMUNOLOGICAL CORRELATES FROM AN EVOLUTIONARY PERSPECTIVE

Amber N. Carrier
May 11,2012

Depression is one of the most frequent causes of disability worldwide. It can
affect the psychological, social, and physical wellbeing of those that suffer from it, the
majority of which are women. Depression has been linked to immune activation as well
as serotonin depletion through a reduction in its precursor, tryptophan. Chlamydia

trachomatis infection and estrogen can influence both the immune system and tryptophan
levels, thereby biochemically inducing a depressive state. If this is the case, the use of
exogenous estrogen through oral contraceptive pills (OCPs) could increase depressive
symptoms, while the use of antibiotics to treat C. trachomatis infection could decrease
depression.
This thesis examined whether depression status in subjects was correlated with
infection and medication use. Women were screened for depression at their annual
gynecological exam, during which time they would receive an STI screen as standard of
care. The study was conducted at the University of Louisville GYN/OB Foundation
clinic and Campus Health Services from 2009-2011. Subjects were given a Beck
Depression Inventory (BDI) to assess depressive symptoms and asked to keep a calendar
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of medication use. Subjects returned after one month to take a second BDI and their
scores and medication calendars were compared with their medical records, specifically
infection status and existing medical conditions.
BDI scores decreased significantly in the follow-up assessment relative to the
initial assessment. This decrease was correlated with the extent to which the subjects
used mood-altering medications. Birth control use was correlated with an increase in
depressive symptoms, but subjects who took mood-altering medication in addition to
birth control were not more depressed than those that did not take birth control. There
were insufficient data to correlate sexually transmitted infections, particularly C.
trachomatis, with depressive symptoms. These findings show that increased hormonal
birth control use is correlated with an increase in depression, but this depression is
ameliorated with the use of mood-altering medication. These results imply that antidepressive medication may be particularly effective in treating depression associated with
estrogen or oral contraceptive pills.
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CHAPTERl
INTRODUCTION

A Brief History of Evolutionary Medicine

Theodosius Dobzhansky once said, "Nothing in biology makes sense except in the
light of evolution." [1] Evolution is a framework upon which all of biology rests; the
concept of change over time in heritable traits has reverberations in each branch of
biology, from anatomy to ecology to genetics. The works of scientists such as Charles
Darwin, lB.S. Haldane, Sewall Wright, and W. D. Hamilton have been accepted as
fundamental to the modern understanding of the biological sciences. However, the field
of medicine, which is founded on biological, chemical, and physical principles, has been
slow to acknowledge how the core principles of evolution may influence the current and
future practice of medicine.
One exception to this generalization is the field of population genetics, which
describes evolutionary change in terms of changing gene frequencies, and has been
integrated into medical sciences for over a half century [2]. Explanations of the
disappearance of the ability to digest lactose as an adult, the lack of alcohol
dehydrogenase in certain groups of people, and the phylogeny of pathogens in order to
predict future epidemics all have origins in evolutionary biology [3].
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Evolutionary medicine seeks to illustrate how and why the human body has innate
vulnerabilities to disease, providing the clinician with new insight into how to respond to
a set of symptoms because the clinician understands that the body works, as Nesse [3]
puts it, as a "product of natural selection with traits more exquisite than any machine."
Though this level of understanding seems as ifit would be intuitive to those who
practice medicine, there has been some reluctance to directly apply evolutionary thinking
to medical practice. This reluctance likely has its roots in our limited understanding of
pathogens; we are still learning not only about the pathogenesis of infectious diseases but
also how the body responds both acutely and chronically to these infections. Many of
these pathogens, such as Varicella zoster in the case of shingles and Helicobacter pylori
in the case of peptic ulcers and stomach cancer are cryptic in their presentation[4]. The
pathology of other illnesses, such as multiple sclerosis and insulin-dependent diabetes
mellitus, may be self-destructive immune responses to seemingly unrelated infections [5,
6]. Of particular concern are pathogens in which transmission is infrequent; these
infections are likely to benefit from long dormant periods and mechanisms for the
evasion of host defenses. A prime example of these types of pathogens is sexually
transmitted infections [4, 7].

STIs and Latent Infections

Sexually transmitted infections are those that are commonly spread through
vaginal, anal, or oral intercourse. These infectious may not be immediately symptomatic,
and some, such as human immunodeficiency virus (HIV), can be present for many years
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before the patient begins to display overt signs of infection [4, 7]. Other STI patients,
such as those that suffer from Neisseria gonorrhoeae, which causes gonorrhea, often
display overt symptoms much earlier, though overt symptomatology is not always the
case. One of the reasons for continued infection and transmission of STIs is that many
sufferers, particularly women, do not display overt symptoms of disease. Because of this
crypticity of infection, sexually transmitted pathogens can initiate long-term infections
with less risk of eradication through medical treatment. Their prolonged infectiousness
facilitates transmission over periods of time that span changes in sex partners [4].
Sexually transmitted infections are very common both in the United States and
worldwide. Women bear a heavier STI burden than men. According to the Centers for
Disease Control, there were over 590 cases of Chlamydia trachomatis infection and 105
cases of gonorrhea per 100,000 women in the United States, as opposed to 219 and 91
cases per 100,000 men for Chlamydia trachomatis and gonorrhea, respectively [8]. In the
case of Chlamydia trachomatis infection, the burden on women is nearly three times
higher than it is for men, and over 1.2 million cases of Chlamydia trachomatis were
reported to the CDC in 2009, but many more infections may remain unreported[8].
Chlamydial infections in women are usually asymptomatic and if left untreated, lead to
pelvic inflammatory disease, the number one cause of infertility related to obstructed
fallopian tubes [8, 9].
One of the reasons that Chlamydiae are able to establish long-term infections is
that they are obligate intracellular pathogens. Such pathogens are difficult for the
immune system to effectively eradicate because they reside within host immune cells; an
immune mechanism to battle such infections includes starving the pathogen by depleting
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essential nutrients such as vitamins, iron, and amino acids [10, 11]. Over the course of its
evolutionary history, however, genitally acquired strains of C. trachoma tis have evolved
the necessary genes to manufacture some of these nutrients, particularly tryptophan.
Tryptophan is an essential amino acid that is restricted, or purposefully removed from
circulation, by an enzyme called indoleamine 2,3-dioxygenase (IDO). The human body
cannot manufacture tryptophan de novo and must obtain it from the diet, but C.
trachomatis carries within its genome the genetic instructions for tryptophan synthase, an

enzyme that manufactures tryptophan from other common molecules. In this way C.
trachoma tis infections may persist as the body's own pool of available tryptophan

dwindles.

Tryptophan and Serotonin

Depletion of the body's tryptophan stores is ultimately harmful for synthesis
pathways that depend upon availability of the amino acid. One of these synthesis
pathways is that for serotonin, a monoamine neurotransmitter found in the GI tract and
the central nervous system (CNS) [12]. Within the CNS, serotonin aids in regulation of
emotional behavior, and as a result is often referred to as a "happiness hormone" despite
the fact that it is not a hormone [13, 14]. Serotonin is also part of the synthesis pathway
of melatonin, an important mood stabilizer and sleep regulator [12]. The most commonly
prescribed class of antidepressants, selective serotonin reuptake inhibitors (SSRIs), act to
increase the availability of serotonin in the synaptic cleft, and therefore increase the
amount of serotonin available to bind to the postsynaptic receptor, by preventing the
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reuptake of the monoamine [15]. This increase in serotonin availability helps the patient
to stabilize mood and has been shown to reduce depressive symptoms a great deal in
those with clinically significant depression [16]. The efficacy of SSRIs in those with
milder depressive symptoms is often disputed because the effect of SSRIs for those with
mild depression is small [17].
Reductions in serotonin availability due to decreased tryptophan may contribute
to depressive symptoms because overall serotonin availability and tryptophan levels have
been correlated [18-20]. Research has indicated that acute tryptophan depletion can
induce depressive symptoms in individuals that had previously experienced depression
[21]. It is thought that tryptophan depletion by the immune system may be the reason
that proinflammatory cytokines induce both depression and "sickness behavior," which is
physiologically almost indistinguishable from depression [22-26]. Such a process might
be occurring in patients infected with Chlamydia, whose immune systems may restrict
tryptophan in order to combat a chronic infection that has evolved a mechanism for
evading tryptophan starvation by manufacturing its own.

Chlamydia trachoma tis and Depression

If persistent Chlamydia trachomatis infection is depleting tryptophan stores, I
hypothesize that women who are suffering from mild to moderate depression will have a
higher frequency of undiagnosed Chlamydia trachomatis than women that show no
depression (Chapter 2). If this is the case, upon diagnosis and treatment, not only should
the infection be cleared, but also depressive symptoms should improve in the subject.
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My thesis research attempted to test this idea. It was conducted at Campus Health
Services, Belknap Campus and the University GYN/OB Foundation to examine if there is
a correlation between undiagnosed Chlamydia trachomatis infection and depression, and
if treatment of the infection ameliorates depressive symptoms in the subject (Chapters 34). Discussion and limitations of the study are included in Chapter 5.
Depression is a leading cause of disability [27, 28], and amelioration of some
depression in the United States could save billions of dollars in health care costs and
reduced productivity due to absenteeism [29]. There has been a great deal of research
into the social circumstances and the biology of depression and its treatment, but little
into the actual primary cause of depression[16, 30]. This dissertation seeks to explore a
potential primary cause of this debilitating illness and provide an alternative treatment
scenario for ameliorating depression that aims to eradicate the primary cause.
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CHAPTER 2

DEPRESSION AND THE IMMUNE SYSTEM

Introduction

Depression is a debilitating illness affecting 15-35 million Americans [31].
Though most people typically experience a depressing situation at some point in their
lives [32] major depressive disorder is defined as a prolonged and unusually severe
period in which normal function is disturbed [33]. Depression has been ranked as the
number one cause of disability worldwide [27-29] and the costs incurred through
treatment and productivity loss are in the billions. Major depressive disorder has a
distinct emotional, social, and physiological effect on the sufferers in all aspects oflife
[34]. Apart from the general malaise and the disability associated with low mood,
depression takes a toll on the social and familial relationships in the sufferers' life.
There is no singular cause of major depressive disorder (MDD); rather, a number
of social and biological factors have been identified as contributing to the development of
disease. Factors such as childhood poverty and a history of abuse and neglect are widely
known to be linked to depression in adulthood[35]. Major life changes and stressors,
including death of a loved one, divorce, and job
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pressure are known social triggers for the disorder [36]. Other factors including
neurochemical imbalances, alcohol and drug abuse, and neuroanatomical differences also
increase the predisposition for developing depression. It is likely that the development of
depression is multi-factorial, with influences from each category of disease causation:
genetic, non-infectious environmental, and infectious [37](Figure 1).
On the basis of high estimates of heritability and the physiological burden of the
illness, some evolutionary psychologists believe that MDD may be an ancient behavioral
adaptation that is somewhat maladaptive in modern environments [34]. Major depressive
disorder usually begins during the first decade after reproductive maturity. Depression
has been reported to result in late menarche, secondary amenorrhea, menstrual
irregularity, and reduced live birth rate, decreasing overall female fertility [38] .
Depression may persist evolutionarily because of compensatory benefits [34], such as
socially appropriate behavior modification, improved social navigation, and avoidance of
social risk [39-42]. Evolutionary psychologists also surmise that depression could be an
adaptation that limits the transmission of causal infectious organisms[43] by encouraging
the individual to rest and avoid others. Alternatively, it could be a side effect of the
immune system's activation against the pathogen itself.
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Figure 1. The triad of disease causation. Virtually every human illness is caused by
at minimum genetic, infectious, or environmental, including social, factors ~ the
majority of diseases are caused by a combination of the three.

Genetic

Environmental
nutrition, toxic chemicals,
low water quality

Infectiou
Virulent pathogens such a
Chlamydia trachomatis

Depression and the Immune System

There have been robust associations between chronic inflammation, stress, and
depression. Major depressive disorder and other psychological disturbances are
associated with increased host cell release of inflammatory markers and cytokines such as
IFN-y, IL-6, chemokines, and acute-phase proteins [44-49] (see Table 1 below). These
markers are modified proteins that serve as signaling molecules in the immune system.
An increase in concentrations of IL-6 and C-reactive protein has been observed in plasma
of depressed patients. Elevated concentrations of IL-1 (3, TNF -0, and IL-6 have been
found in the peripheral blood and cerebrospinal fluid of depressed and/or suicidal patients
[47,49-51]. Other chemokines and acute phase proteins elevated in patients with major
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depression include a-I-acid glycoprotein, a-I-antichymotrypsin, haptoglobin[44, 52],
human macrophage chemoattractant protein-I (MCP-I), soluble intracellular adhesion
molecule-I (s-ICAM-I), and E-selectin. IL-2 production is reduced in depressed,
dysthymic, and atypically depressed patients [50, 53, 54], but less so in the atypically
depressed group that can still experience elevated mood in response to positive life
events. These studies illustrate that there are differences in the presence of these
immunological molecules in depressed vs. non-depressed patients, and that their
concentrations may sometimes correlate with symptom severity [53, 54].

Table I. Immune molecules associated with depression. This non-exhaustive list includes molecules
linked to both depression and sickness behavior.

Molecule

I'

'11\~)

' Ty~e

. ,<

Role in immune System

".

"

.

,

.,.
Binds to microbes and dead and dying cells to initiate
complement binding during inflammation

C-Reactive Protein

Acute phase
protein

Interferon-a

Type I Interferon

Produced by leukocytes, involved in innate immune
response against viruses

Interferon-y

Type II Interferon

Promotes NK cells, Th 1 differentiation, leukocyte
migration, antigen presentation on macrophages

Interleukin-l p

Cytokine

Produced by macrophages to mediate inflammatory
response

Interleukin-2

Cytokine

Interleukin-6

Cytokine

Produced by Thl cells; stimulates growth and
differentiation of T-cells in response to antigen
binding
Secreted by T -cells and macrophages to stimulate
immune response, particularly to infection

Tumor Necrosis
Factor-a

Cytokine

Induces apoptosis, inflammation; inhibits
tumorigenesis and viral replication
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The question of exactly how cytokines may induce a depressive state remains in
debate. Cytokines circulating in the bloodstream do not typically cross the blood brain
barrier (BBB) but are transported into the brain via other means, such as
circumventricular organs and carrier molecules [55]. Pro-inflammatory cytokines,
particularly IL-l(3, TNF-a, IFN-y, and IL-6, partially mediate communication between
the brain and the immune system through a saturable blood-to-brain transport system [55,
56]. It is possible that cytokines and the immune system may influence depression by
shunting valuable precursor molecules away from pathways necessary for
neurotransmitter production. Tryptophan (Trp), an essential amino acid, is the precursor
for the production of the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) and
its hormonal derivative, melatonin (N-acetyl-5-methoxytryptamine), both of which are
involved in mood regulation [18, 19, 57-62]. Serotonin is largely responsible for mood
regulation within the brain. The most commonly prescribed class of anti-depressants,
SSRIs, act to inhibit the reuptake of the chemical in the presynaptic cleft within the brain,
thereby increasing the amount available for action [15]. The immunomodulatory enzyme
indoleamine 2,3-dioxygenase (IDa) is up-regulated by IFN-y and other pro-inflammatory
cytokines and functions to cleave tryptophan into kynurenine within extra-hepatic tissues
[48,61-69]. When IDa cleaves the indole ring of tryptophan [64], it not only depletes
the host and parasite of an essential amino acid, but also produces proapoptotic
precursors of the kynurenine (kyn) pathway and toxic oxygen radicals [61, 62, 66, 68, 70,
71]. Once this reaction takes place, there is less available tryptophan for serotonin
production, and serotonin levels drop in the central nervous system, resulting in
depressive symptoms [48]. Additionally, the intermediates of the kynurenine pathway,
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collectively known as the kynurenines, have been shown in studies to be neurotoxic,
although once transported away from the CNS they can be used to produce nicotinamide
adenine dinucleotide (NAD), an important co-enzyme involved in energy metabolism
[48] (Figure 2).
During serotonin production, tryptophan is hydroxylated by the enzyme
tryptophan hydroxylase (TPH) into 5-hydroxy-L-tryptophan, which is cleaved by an
aromatic amino acid decarboxylase into serotonin (Figure 2). Since its oxygenation by
TPH is the rate-limiting step in the serotonin synthesis pathway, levels of tryptophan and
serotonin have been correlated in cerebrospinal fluid (CSF) [18-20, 72, 73].
Additionally, the use of radiopharmaceutical tryptophan and PET scans have confirmed
the correlation between trp levels and serotonin synthesis in the brain [72].
Polymorphisms in the TPH gene have been linked with suicidal behavior [18,20] and
variations in the levels of serotonin or its receptors and transporters have been associated
with major depressive disorder. The addition of an acetyl group, followed by a methyl
group, yields the neurohormone melatonin (Figure 2), produced by the pineal gland in the
absence oflight [74]. Melatonin disruption leads to seasonal affective disorder (SAD)
through a mechanism that may involve stimulation of type 1 T-Helper (Thl) cells and
other lymphocytes to produce cytokines such as IL-2, IL-6, and IFN-y [74]. Exogenous
tryptophan has been used as a treatment for both depression and sleep disorders, though
the most common treatment for depression is currently the use of SSRIs [75].
When tryptophan is catabolized by IDO or tryptophan 2, 3-dioxygenase (TDO), a
more specific enzyme that is known to exist only within the liver, the availability of the
substrate for serotonin synthesis becomes limited. Depressive symptoms are found in
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patients that have reduced serum tryptophan levels due to elevated IDO or TDO activity
[19,58,60,62]. Since interferons are also potent mediators oflDO activity [61, 64, 69,
74, 76, 77], elevated IDO activity and the subsequent drop in tryptophan levels due to
inflammation could cause a decline in serotonin levels and a noticeable change in mood
and demeanor.
Proponents of this "cytokine hypothesis of depression" are split on whether
cytokines are the cause of depression or are the mechanism by which another "insult"
leads to depression. Smith first suggested in 1991 that depression was associated with an
increase in secretion of IL-l by macrophages in his "macrophage theory of
depression" [78]. Maes also believed that circulating monocytes and macrophages result
in the increase of depression in patients [79]. Studies involving laboratory animals have
shown that presence of inflammatory cytokines in the brain result in "sickness behaviors"
that are indicative of depression, including anorexia, sleep disturbances, and the inability
to feel pleasure. Inflammatory cytokines also have a stimulatory effect on the HP A axis,
which modulates the stress response, depression, and immunity [44]. Cytokines disrupt
proper serotonin, norepinephrine, and dopamine metabolism in neural centers that
regulate emotional response. However, cytokines do not have the ability to cross the
blood-brain barrier because of their size. Consequently, current research is focusing on
exactly how these molecules can be found in the healthy brain. It is postulated that
increased cytokine levels due to inflammation may degenerate the blood-brain barrier,
thereby enabling cytokines and immune markers to enter the brain and influence mood
[80].

13

Cytokines such as IL-6 and IL-2 are associated with high Hamilton Depression
Scale (HAM-D) scores in patients with chronic illnesses such as decompensated heart
failure, hepatitis C, certain cancers and multiple sclerosis [47, 62, 81, 82]. A study by
Appels et ai. in 2000 showed higher antibody titers in depressed and

e~hausted

patients

who were receiving treatment for a coronary lesion [83]. These patients also showed
elevated IL-1~, IL-6, and TNF -u. Evidence that exogenous administration of cytokines
(particularly IFN-a, TNF-a, and IFN-y) results in an illness that is identical to major
depression provides support to the argument that immune function, particularly
inflammation, contributes to a depressive state [44,84,85]. This "sickness behavior" is
often caused by up-regulation of IDO and tryptophan depletion, and it responds well to
antidepressants [44, 86].
Medication administered to depressed patients has also been shown to have
immunomodulatory effects. Antidepressants inhibit the production of proinflammatory
cytokines and stimulate the release of anti-inflammatory cytokines; alternative
antidepressant strategies such as electroshock therapy appear to attenuate the immune
response, leading to decreased depressive symptoms [44]. Patients that have a history of
impaired response to antidepressants typically display increased blood cytokine loads,
particularly IL-6 [44, 52]. Anti-depressants treat immune-related depression but typically
only address the mood-related symptoms rather than the outwardly physiologic
symptoms such as lethargy, loss in appetite, and difficulty concentrating [78].
Additionally, cytokine antagonists such as IL-1 receptor antagonist appear to have antidepressive effects [22, 78].
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The impact of stress may also drive the development of immune-related
depression in an otherwise healthy patient. Literature has suggested that psychological
stress can stimulate the proinflammatory response [44]. Psychological stress is a causal
factor in major depression and stressful events often precede depressive episodes. Both
acute and chronic stresses are associated with increased production of proinflammatory
cytokines and a decrease in circulating anti-inflammatory cytokines.
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Figure 2. Tryptophan and the IDO pathway. The amino acid tryptophan is converted by tryptophan
hydroxylase ultimately into serotonin, a neuroamine responsible for the maintenance of mood in the brain.
However, if tryptophan is cleaved by IDO it results in the production of the neurotoxic kynurenine.
Kynurenine is cleared by conversion into other necessary macromolecules, notably niacin and NAD.
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Depression and Co-morbidity

Depression is frequently co-morbid in illnesses in which immune dysfunction is
apparent [78]. Many illnesses are known to involve or probably involve immune-related
depression. Several of these diseases are considered below. I will first discuss immunerelated depression in Polycystic avary Syndrome patients. Then I will discuss
depression in atherosclerosis patients. Finally I will discuss the comorbidity of
depression with infection.

Polycystic avary Syndrome
Polycystic ovary syndrome (PCaS) is associated with alterations in mood. The
characteristics associated with pcas, including abdominal obesity, acne, and hirsuteness,
can lead to a depressed mood [87]. Unfortunately, few studies have assessed the comorbidity of PC as and mental illnesses such as major depressive disorder. Twenty to
sixty-five percent of PC as patients are more depressed than controls [46, 80, 88-90].
Women with pcas were far more likely to present with other mental illnesses,
particularly somatic illnesses such as anorexia nervosa and sleep disorders [80]. BMI,
age, education, marital status, and employment did not explain the association of
depression with pcas.
Though obesity is a known risk factor for depression, PCaS-related obesity does
not account for the co-occurrence of major depressive disorder [80, 91]. In fact, obese
women with pcas have approximately six times the risk of developing major depressive
disorder than obese women without pcas, suggesting that a PCaS-related factor may be
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influencing the development of depression [80, 92]. abesity induces over-expression of
such inflammatory markers as CRP and TNF-a, which is in turn associated with insulin
resistance [46, 93]. Decreases in adiposity have been associated with decreases in freely
circulating inflammatory markers [46, 99]. However, pcas patients, including those
with normal BMIs, experience chronic low-grade inflammation with elevated C-reactive
protein, TNF-a, IL-6, neutrophils and total leukocytes compared with age and BMImatched controls [94-99]. Another proinflammatory marker, macrophage migration
inhibitory factor (MIF), is elevated in pcas patients independently of weight [100]. The
genes for cytokines involved in the PCaS-related chronic inflammatory response,
including TNF-a and IL-6, have been investigated in order to deduce the nature of the
association between inflammation and pcas, but no PCaS-associated polymorphisms
have as of yet been identified [98, 101].

Atherosclerosis
Depression is associated with atherosclerosis and may occur prior to diagnosis.
Depressed patients with no existing knowledge of cardiovascular health status display
increased arterial stiffness [102, 103]. Patients with diabetes mellitus (DM) who score
higher than lOon the Beck Depression Inventory are more likely to suffer from
cardiovascular and dyslipidemic disorders [104]. This correlation is strong enough to
suggest that physicians that notice depression in both DM and non-DM patients should
consider a cardiovascular evaluation[104, 105].

Inflammation in the arterial wall is a

key component of the cascade of atheroma formation. Leukocytes flood to the site of
endothelial injury, and some of these, particularly macrophages, can sequester circulating
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cholesterol and transform into foam cells within the lesion [106, 107]. Pro-inflammatory
cytokines signal this inflammatory response, which can be detected both locally and
systemically. In fact, circulating pro-inflammatory markers such as IL-6 and CRP can be
used in a clinical setting to as a biomarker for atherosclerosis [106, 108]. Other immune
markers correlated with depression are elevated in atherosclerotic patients; Elovainio et

ai. found that depression was only associated with atherosclerosis in women with high
IDO activity [109].

Acute and Chronic Infections
A number of acute infectious illnesses such as influenza, gastroenteritis, and
infectious mononucleosis (Epstein-Barr infection) are associated with both somatic and
mood-related depression symptoms [55]. A combination of any or all offatigue,
decreased psychomotor skills, anorexia, somnolence, lethargy, aches, cognitive
disturbance, depressed mood, a sense of guilt, and difficulty in decision making have
been reported in those suffering from influenza and other viral infections. Viral
infections stimulate the production of type I interferons and activate NK cells; once
infection has been established CD8+ Tc cells and CD4+ Th1 cells mount a more precise
antiviral response [110]. This response includes the production ofIL-2, IFN-y, and tumor
necrosis factor by Th1 cells. Some viruses, particularly those that exist as chronic
infections, can either evade host defenses or cause immunosuppression.
Extracellular bacterial pathogens incite an innate inflammatory response and
cause to the release of inflammatory cytokines. However, innate immunity has little
effect on intracellular bacteria, but these pathogens can induce a cell-mediated response
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[110]. Cytokines secreted by CD4+ T cells, particularly IFN-y, direct macrophages to
assist in killing ingested pathogens. Many common bacterial infections in the United
States, including Campylobacter jejuni, the Salmonella group, Streptococcus

pneumoniae, and Streptococcus pyogenes can induce symptoms similar to depression,
particularly malaise, muscle weakness, and fatigue [110-114]. These symptoms are due
to the immune response to these infections. The sickness behavior associated with these
infections is nearly synonymous with depression and depressive symptoms [22]. Patients
that are receiving interferon treatment for various infections often develop depression as a
side effect within as little as one month from the initiation of treatment.

Immune system-related depression is relatively common and sickness behavior is
nearly identical to it. Because of this, it is logical to associate other illnesses in which an
inflammatory response is generated with possible depression symptoms, particularly
those with an infectious component. One bacterial infection that has not been examined
in adequate detail with regard to its possible relationship to depression is Chlamydia

trachomatis.

Chlamydia and Depression

Chlamydia trachomatis warrants particular scrutiny as a possible cause of
depression due to some serovars' ability to produce tryptophan when IDO is elevated.
Chlamydiae invade and live within host cells as obligate intracellular pathogens [64, 65,
115]. They exist within humans in two forms: the infectious yet metabolically inert
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elementary body (EB), and the non-infectious, intracellular but metabolically-active
reticulate body (RB) [65]. Conversion between the two forms takes place within the host
cell. Three biovars of C. trachomatis have been linked with human disease: ocular
trachoma (caused by serovars A, B, Ba, and C), genital trachoma (serovars D-K), and the
severe and systemically invading lymphogranuloma venereum (LGV) (serovars Ll, L2,
and L3) [116]. There is very little cross-over between serovars and their infecting sites;
the ocular serovars very rarely infect the genital tract, and the genital serovars generally
only infect the eyes of infants when they pass through the birth canal [117]. The ocular
and genital trachoma serovars are considered non-invasive, but the more rare LGV
serovars proliferate within monocytes and lymphatic tissues and are highly invasive. The
genital variants encode functional tryptophan synthase whereas the ocular variants do not
[65, 116, 117]. A trpRBA operon codes for the tryptophan synthase alpha and beta
subunits and the trp operon repressor. The deactivation of the repressor when tryptophan
is scarce allows tryptophan synthase to produce tryptophan from indole, a readily
available waste-product of many common vaginal flora [117]. This rescues Chlamydia
from IFN-'1-induced tryptophan restriction in vitro.
As obligate parasites of human cells, chlamydiae can largely evade detection by
the humoral immune system. Some cytokines, though, are effective against C.
trachomatis. IFN- '1 functions to clear C. trachomatis infection by up-regulating the

production ofIDO. When IDO cleaves the indole ring of tryptophan [64], it not only
depletes the host and parasite of an essential amino acid, but also the by-product,
kynurenine, is toxic to Chlamydiae [61, 62, 66, 68, 70, 71]. Tryptophan depletion starves
Chlamydiae but often leads to the formation of a persistent, aberrant state of infection
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[61, 76, 118, 119]. Under this state, infections can become chronic, particularly the
genital strains that are able to synthesize tryptophan de novo and evade the immune
system's IDO response.
Because of the ability of some persistent strains of C. trachomatis to synthesize
tryptophan, a long-term infection is possible, even during immune activation and
tryptophan restriction by IFN-y and IDO. However, long-term immune activation and
elevated IFN-y levels may lead to other types of pathology such as the occurrence of
depression due to a loss of serotonin. Because of the crypticity associated with C.

trachomatis infections, particularly in the 70% of infected women that are asymptomatic,
long-term C. trachomatis infection may lead to long-term symptoms of depression
through biochemical means.

Peri menstrual response to Infection and Depression

Depressive symptoms in women are more frequent between puberty and
menopause, and major depressive disorder (MDD) is twice as likely to occur in women
as in men [66, 120-123]. Transitory depression is common and often occurs during major
hormone fluctuation periods such as pregnancy, parturition, and menopause [120-122].
Estrogen fluctuation has been incriminated as a cause of this depression in part because
of its effects on the IDO enzyme [123] and its temporal correlations with MDD [120].
Additionally, progesterone and its metabolites are correlated with peri menstrual
symptoms such as fluid retention and emotional turmoil[124]. Both progesterone and
estrogen dysregulate serotonin synthesis, and peri menstrual dysphoric disorder (PMDD)
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and depression in women responds to treatment with SSRIs [125] and
estrogen/progesterone containing low-dose birth control [123].
Estrogen and progesterone also modulate immune activity. Elevated progesterone
during the luteal phase of the menstrual cycle is associated with a shift in immunity away
from the Th1 response, leading to a decrease in the production ofIFN-y and other
cytokines that are more effective in controlling intracellular bacteria[126]. Estrogen,
which up-regulates IDO activity [126-128], is also elevated over the majority of the luteal
phase. This appears to be a compensatory mechanism for the down-regulation ofThl
activity during the luteal phase in order to provide some defense against intracellular
bacteria by restricting tryptophan. This defense would be relatively ineffective against
any genital serotypes of C. trachomatis because they can synthesize their own tryptophan
[126]. Accordingly, transitory depression and C. trachomatis infection both covary
within the menstrual cycle; both are exacerbated during the late luteal phase and the first
few days of menstruation [124]. Depressive symptoms have been known to occur with
sexually transmitted infections (STIs) [129] and C. trachoma tis in particular [28, 130].

In summary, depression is a debilitating illness with a distinct immunological
component, and both hormones and infection might be key players in this interaction.
The enzyme IDO functions to deplete tryptophan stores, and it is up-regulated by both
estrogen and the immune system in response to intracellular infections such as C.
trachomatis. Iftrp stores are depleted, there is less substrate with which to produce

serotonin, and depression may result.
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CHAPTER 3

MATERIALS AND METHODS

This clinical study (IRB 09.0226) of depression sought to detennine whether
antibiotic treatment of Chlamydia trachomatis infection was associated with a subsequent
amelioration of depressive symptoms.
The goal was to enroll 100 patients from the University GYN/OB Foundation
clinic that displayed evidence of depression during their annual gynecological check-up.
This evidence included a physician's diagnosis of depression or the display of overt
depressive symptoms. Subjects were pre-screened for eligibility by the physicians and
medical assistants before their exams. Women between the ages of 18 and 40 who were
non-menopausal (naturally or surgically), with relatively nonnal menstrual cycles and
depressive symptomatology were invited to participate in the study. Each patient was
compensated $10 at the initial visit, and $30 at a return visit one month later to assess
depressive symptomology.
A medical assistant asked eligible patients if they would like to participate in a
volunteer questionnaire study on mood in gynecology patients. Each interested subject
was directed to the researcher who gave her a flyer and explained the details of
participation, the need to keep records on her medication use, and to return for a followup visit one month after the initial visit
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The patient was then given time to consider participation away from the
researcher. If she agreed to participate she returned to the researcher to begin the consent
process.
The consent process consisted of the patient signing a Subject Informed Consent
Document (SIC, Appendix A) and a HIP AA Research Authorization (HIP AA-RA,
Appendix B) document. The researcher discussed each document with the subject,
starting with the SIC so that the subject was aware of the scope and risks of the study
before continuing. Each paragraph was explained orally and time was given for the
subject to read it if she so chose. Once the subject had signed the informed consent
document, the researcher discussed the HIPAA-RA with the subject in a similar manner
and explained to the subject that in order to participate in the study the researcher would
need access to some of the subject's medical records. The researcher then detailed the
security procedures that protect the subject's Personal Health Information (PHI).
Consenting subjects signed two copies of each document; one remained with the subject
while the second remained with the researcher. After the subject's first visit, the
researcher presented each SIC document to the three Principal Investigators of the study
for signatures. The signed document's photocopy was mailed back to the subject.
Once the SIC and the HIPAA-RA were completed, the subject was asked to
complete Research Study Questionnaire (RSQ) to confirm her eligibility for the study and
a Beck Depression Inventory II (BDI). The RSQ (Appendix C) consisted of six openended questions intended to confirm the subject's age and health status, as well as to
ensure accuracy when matching the patient's medical records to her BDI and calendar
results. The RSQ also confirmed that the patients were pre-screened correctly. The BDI
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(Appendix D), a widely respected standard in the psychological community for
quantifying levels of depression, was used to quantify the degree of depression in the
subject. Each question was read to the subject to reduce any effects of variation in
literacy and language on the results of the questionnaire or BDl.
The BDI assesses two measures of depression -- the psychological/cognitive
symptoms and the physiologic (somatic or non-cognitive) symptoms [131]. The
cognitive symptoms, including thoughts of suicide, pessimism, and past failure, are
covered in questions 2,3, 5- 9, and 14. Somatic/non-cognitive symptoms, including loss
of energy and agitation, are illustrated by questions 1,4, 10-13, and 15-21. Question 1,
which addresses sadness, and question 10, which addresses crying behavior, have been
associated with both cognitive and somatic symptoms, but are often classified as
primarily somatic [131, 132].
After the patient completed these documents, the researcher scheduled each
subject to return in approximately four weeks for her follow-up appointment. The
researcher explained to each subject how to complete the calendar, document all
medication use, and mark the day menstruation begins. The researcher requested that the
subject note if there was a significant life event (described orally as a "car accident,
family emergency, etc. ") that might influence the results during the study period. The
researcher also explained that this information on life events could be helpful but was not
required and that such an event would not exclude her from the study. The researcher
then filled out the receipt (Appendix E), noting the subject's address and phone number,
and gave the subject the first portion of her compensation. The subject was sent home
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with a calendar (Appendix F) stapled to a purple file folder so that the calendar could be
readily accessed.
Deviations from the above protocol were made only in the event that the subject
had a question about any aspect of the study. Such deviations were noted in the research
database.
A few days prior to each follow-up appointment (average 2.5 days), the subject
was given a phone call to remind her of the study appointment and to confirm that the
subject would be able to attend and return her calendar. If the subject needed to
reschedule the appointment, this accommodation was made. At the follow-up
appointment, the subject completed a second BDI and RSQ . She was compensated $30
at this visit and filled out another receipt. See Figure 3 below for more information about
the timeline of subject interaction.

Figure 3. Timeline of Events from initial subject interaction to follow-up.
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The GYN/OB Foundation Clinic tests for C. trachomatis as part of the procedure
associated with pap smears. It was expected that approximately 25% of the subjects
recruited would test positive for C. trachomatis. If a patient tested positive for C.

trachomatis or any other SII, the standard follow-up of the GYN/OB Foundation
involved patient notification and mailing the standard antibiotic treatment to the patient.
In the case of C. trachomatis, treatment was typically one dose azithromycin, 1 g by

mouth. Some subjects, particularly those with penicillin allergies, were treated instead
with rocephin (ceftriaxone) plus erythromycin base, amoxicillin, erythromycin
ethyl succinate, or doxycycline (Table 2). Patients were instructed to record antibiotic
usage on their calendars, as well as on the follow-up RSQ. These documents, when
compared with the subject's medical records, allow identification of subjects who were

Chlamydia-positive but did not complete the prescribed medication regimen. The RSQ
and calendar also allowed detection of any other medication use that might influence the
results of the BDI and sometimes provided indications ofa subject's immune status. The
second BDI was intended to allow assessment of the antibiotic's effects on depressive
symptoms. Each BDI was scanned upon completion to detect abnormally high scores
that might indicate a need for immediate care from a mental health professional. If no
such problem was found, the initial and final BDI were scored after the subject completed
the study to maintain confidentiality and impartiality.
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Table 2. Medications prescribed for treatment of Chlamy dia infections.

Azithromycin

Azalide (macrolide)

19 by mouth

Cephalosporin

250 mg intramuscular injection

Erythromycin base

Macrolide

500 mg by mouth for 1 day

Amoxicillin

~-lactam

500 mg by mouth 3xJday for 7 days

Rocephin
(ceftriaxone)

Erythromycin

800 mg by mouth 4xJday for 7 days or
Macrolide

ethylsuccinate
Doxycycline

400 mg by mouth 4xJday for 14 days
100 mg by mouth 2xJday for 7 days

Tetracycline

After each subject completed her initial and final visit, both of her BDIs were
scored and her medical records examined to determine her Chlamydia-positive status at
the time of the initial visit. Any other diagnoses at this visit were also noted as well as
any medications prescribed at the initial visit or later. When the researcher was taking
notes only a three-digit study code identifier was used rather than the subject's actual
name, and any notes on paper were shredded in a diamond shredder after they were
entered into the subject database.
All study data were entered into a password protected spreadsheet on an Apple
Mac Book Pro running Mac OS X 10.7.2 (Lion). The spreadsheet was passwordprotected for both changing and viewing the document. No subject identifiers (such as
name, birth date, address, etc.) were entered onto the spreadsheet; the date of the BDI
administration was therefore the only possible identifier entered. The subject's paper
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documents, including her SIC, HIPAA-RA, RSQ, BDI, and receipts, were placed in the
file folder with her calendar, marked with her three digit ID code on the tab, and stored in
a locked filing cabinet in the Life Sciences Building at the University of Louisville. The
only two individuals in possession of a key to this cabinet were Amber Carrier and Paul
Ewald. All data from paper documents, excluding any subject identifiers, were entered
into the subject database. Further analysis was conducted from this de-identified data set.

Revised Protocol

It was very difficult to obtain the number of subjects as originally planned.

Explanations for this difficulty are discussed in Chapter 5. The following changes in
protocol were made in a second phase of the study to facilitate recruitment.

1. In November 2010, I spoke with Dr. Phillip Bressoud, Executive Director of
Campus Health Services, and Dr. Kari Zahorik, Medical Director of Campus
Health Services, about the possibility of working at Campus Health Services,
Belknap Campus (215 Central Ave, Louisville, KY 40208) as a second subject
recruitment site. The expected advantages of this site were higher availability of
potential subjects, familiarity of potential subjects with simple research projects,
and a high rate of STI transmission among college students. This addition
required an amendment to the IRB protocol, approved January 27, 2011. I
therefore began to recruit participants from this office in January 2011.
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2. Campus Health Services does not automatically test for STIs unless the test is
covered by the subject's health insurance, and one third of the student population
does not have health coverage. An arrangement was negotiated with Louisville
Metro Public Health and Well ness Department (LMPHW) to test for Chlamydia
and Gonorrhea in uninsured subjects. I was provided with the test kits, and the
staff at CHS utilized the LMPHW kits with uninsured subjects that agreed to
participate in this study. I couriered the kits to LMPHW for testing and the results
were faxed back to CHS.
3. Purple post-it notes identifying subjects that might be eligible for the study were
attached to the medical charts of women scheduled for an annual exam each day
that I was present. This served to remind the medical assistants to pre-screen
potential subjects.
4. Several subjects at Campus Health Services had privacy concerns with mailing
addresses and requested that I return their fully signed SIC at their next visit. I
complied with these wishes, and gave future subjects this option without
prompting.
5. An advertisement for the study was placed in the SGA Student News. Once
students responded via email, they were sent identical emails explaining the study
and encouraging them to make an appointment at Campus Health. This was done
to encourage potential subjects to make a gynecologic appointment at Campus
Health, and served the greater public good by encouraging women to obtain their
annual exam. A copy of the ad and the email can be found in Appendix G.
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6. Because potential subjects were not often reporting depressive symptoms even
though their BDI scores indicated low levels of depression, the decision was made
to recruit all gynecological subjects into the study, not just those that were
displaying overt depressive symptoms during their exam.
7. Two research staff members, Laura Ovaitt (PhD student) and Samiyyah Sledge
(undergraduate student) were added to the study, and recruited subjects under my
supervision. Any subjects recruited by them are noted.

Table 3. Timeline of events pertaining to the Study

Date

Event

6/22/09

IRB Approval of project

10/1109

Recruitment Begins in GYN/OB Foundation

1127/11

CHS added as second recruitment site

3/14111

Advertisement submitted to Student News

9121111

Samiyyah Sledge added as study personnel

10/5/11

Laura Ovaitt added as study personnel

12/1111

Recruitment ends at OB/GYN

12/1111

Recruitment ends at CHS

1131112

Data Analysis

Subjects might alter their tendency to report depressive symptoms to
accommodate the researcher or because of a psychological effects of medical attention or
participation in the study. In such situations, the BDI test scores could change even
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when the underlying state of depression was not altered by antibiotic treatment. The
questionnaire was administered to subjects who were not infected with C. trachomatis so
that any reductions in depression associated with antibiotic treatment could be compared
with changes among subjects who were untreated. If the results showed that antibiotic
treatment of C. trachoma tis infection was associated with amelioration of depression, this
association could serve as a basis for a follow-up case-control study.

Statistical Analysis

The presence of a non-parametric sample was confirmed via a Shapiro-Wilk test,
a test appropriate for determining the normality of small sample sizes [133]. Normality
plots were also constructed to graphically assess normality of the data. When
distributions were non-normal, Wilcoxon signed rank test were used to determine
whether amelioration of depression was associated with the second administration of the
BDl. This test was chosen because the initial and final BDI scores are related and the
differences can be considered ordinal. A Mann-Whitney U test was conducted when
groups of paired scores were compared with each other. BDI sub-scores were assessed
using cognitive vs. somatic symptoms to determine if the somatic symptoms that are
similar to sickness behavior decreased when the subject took medication. Primary
statistical analyses were conducted using SPSS version 20 [134], on a MacBook Pro
running Mac OS X 10.7.2 (Lion). Power analyses were conducted using the freeware
G*Power 3.1.3 for Mac [135,136].
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CHAPTER 4

RESULTS

Subject Demographics

Twenty-four subjects completed the study. Nine additional subjects completed the
first BDI but did not complete the study or were otherwise non-compliant (Table 4). The
majority of subjects self-identified as Caucasian (16 total, two from GYN/OB and 14
from CHS) but other categories included Hispanic (two from OB/GYN), Black (four
total, two each from both sites), Asian (one from CHS) and of mixed race (one from
CHS).

Descriptive Statistics

BDI scores and measures of variation in these scores for the two groups of study
subjects are presented in Table 5. To assess whether the data met the requirements for
parametric statistical testing, variances were compared and normality was evaluated.
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Table 4, Subjects who did not complete the study or were otherwise non-compliant.
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007

OB/GYN

No Follow-up

008

OB/GYN

No Follow-up

009

OB/GYN

No Follow-up

011

OB/GYN

No Calendar

013

CHS

No Follow-up

017

CHS

No Follow-up

019

CHS

No Follow-up

020

CHS

No Follow-up

033

CHS

No Follow-up

,I•

Table 5, Descriptive Statistics for subjects for whom BDI data is available,

GYN/OB

CBS

Combined

Mean Age

31

24

26

Number of Subjects

8

17

25

Mean Initial BDI

27.38

8.75

14.68

Mean Final BDI

17.00

7.41

10.48

Mean Difference

-10.38

-l.34

-4.20

Variance of Difference

152.26

37.97

88.42

Std. Error Difference

4.36

l.50

l.88
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The variances of the changes in BDI scores in the OBGYN (N=8) and CHS
(N=17) populations were significantly different (Table 5, row 6, columns 1 and 2,
F=8.286, p=0.009, Levene's test for unequal variances). The initial BDI scores deviated
significantly from normality, as did difference in BDI scores (final score - initial score)
(p=0.002 and 0.010 respectively, Shapiro-Wilk test, Figure 4). The final BDI scores did
not (p=0.073, Figure 4). The threshold used for statistical significance was a=0.5. By
this criterion, the changes in BDI scores in two subject pools were not significantly
different from each other (N=25, p=0.086). The lack of statistical significance does not,
however, provide a justification for combining the two populations because the nearness
to statistical significance suggests that such a grouping would risk incorporation of a
Type IT statistical error, particularly since power is low (13=0.59 for the difference).
Considering this indication and the significant differences between the populations in
normality and variance ofBDI scores (see above) tests were run separately on each group
whenever sufficient data were available within each group.
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Figure 4. Nonnality plots with initial BDI score (upper left), final BDI score (upper right), and difference
(final minus initial, lower left)). Means are given in Table 5 (rows 3, 4, and 5 of column 3).
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The BDI scores were significantly lower in the follow-up assessment relative to
the initial assessment for the OB/GYN sample (p=0.035, Figure 5), but not in the CHS
sample (p=0.36, Figure 6). A Fisher's combined probability test of both WilcoxonSigned Rank scores indicated that overall the level of depression in the follow-up tests
did not significantly decrease (p>0.30, X2 =3.812, df=4) . Subject 011 was included in
this analysis because BDI data was available for her.
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Figure 5. Wilcoxon Signed Rank of initial and final BDI scores of the OB/GYN sample.
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Figure 6. Wilcoxon Signed Rank test of the initial and final BD! scores for the CHS sample.
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Because of the similarity between sickness behavior and the non-cognitive
symptoms of depression, the initial and final BDI scores were subdivided according to
cognitive (affective) and non-cognitive (somatic) sub-scores (Table 6). The OB/GYN
and CHS populations differed significantly within these categories for the initial and final
scores (Table 6, row 1 versus row 4 and row 2 versus row 5; Table 7, rows 1 and 2.
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Table 6. Affective and Somatic BDI scores for subjects. The affective BDI scores for all subjects ranged
from 0-13 (out of a possible 24), and the rough somatic BDI scores ranged from 0-32 (out of a possible 39).

-0.53
9.43
5.86
-3.57

0.67
0.44
1.29
1.60
1.56

7.60
3.27
11.62
17.81
16.95

5.12
-1.50
19.00
10.57
-8.43

0.96
1.16
3.30
2.09
3.20

15.61
18.73
76.33
30.62
71.62

Table 7. Comparison ofBDI sub-scores in the CHS and OB/GYN populations. Entries are p values for the
inter-site difference in the initial scores, the final scores and the change in the scores (final minus initial).
Significant results are marked with an asterisk (Mann-Whitney U tests). Means for these categories are
given in Table 6.

0.016*

0.006*

0.262

0.095

The somatic sub scores were significantly lower on the final visit relative to the
initial visit for the OB/GYN population but not for the CHS population (Table 8, row 2).
A combined probabilities test indicated that overall the results were not significant
(p>0.30, X2 = 3.79, df=4) . The affective sub scores were not significantly lower on the
follow-up visit for either group (Table 8, row 1: p>0.30, X2 = 3.40, df=4, combined
probabilities test).
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Table 8. Comparison of change in BDI sub-scores in the final visit relative to the initial visit. Entries are p
values for the differences between final and initial visits. Means for each category are given in Table 6. *
denotes a statistically significant difference

Affective

0.089

0.223

Somatic

0.028*

0.452

Only one subject tested positive for C. trachoma tis. I therefore could not assess
whether pre-existing C. trachomatis infection was associated with higher BDI scores.
Five subjects were infected with a sexually transmitted infection of some kind -- one each
with trichomonas, chlamydia, and HPV; and two with bacterial vaginosis. Mean BDI
scores for each group are presented in Table 9. The presence of a sexually transmitted
infection was not significantly associated with initial, final, or overall change in BDI
scores (p>O.l for all comparisons, Mann-Whitney U test). Subject 011 was included in
this analysis because the BDI data was available for her. Because of the limited number
of subjects that were STI-positive, only the pooled (CHS + OB/GYN) sample was
analyzed.

Table 9. Mean BDI scores of subjects based on infection status. There were no significant differences in
scores between those that were infected with an STI vs. those who were not.

Initial BDI
Final BDI
Difference

8.80
-7.20
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10.90
-3.45

Medication Analysis by class

The large variety of medications used by the subjects (Table 10) and the small
number of subjects prohibited statistical analysis on a medication-by-medication basis.
Other than hormonal birth control, few medications were taken by more than one or two
participants. Many of the medications, however, belonged to a smaller number of classes
of drugs, which were prescribed for the similar reasons (Table 10). Medication
categories were therefore used as variables in lieu of particular medications and all tests
were run on all subjects from both study groups combined.

Table lO. Medications used by patients. A detailed list of these medications is included in Appendix H.

OTe Pain Relievers
Mood Medications

acetaminophen, aspirin, ibuprofen
amitriptyline, bupropion, duloxetine, fluoxetine,
lamotrigine, sertraline, trazadone, zolpidem
amoxicillin, azithromycin, clindamycin,

Antibiotics

doxycycline, metronidazole
Other OTe Medications

azo yeast, melatonin, pepto bismol, prilosec, zantac

Mood-altering medication is expected to ameliorate depressive symptoms. Pvalues associated with mood-medication are therefore reported as one-tailed. The use of
a mood-altering medication was significantly correlated with a decrease in BDI scores
(one-tailed p=0.024, Table 11 row 2).
None of the other classes of medications used were significantly associated with a
change in BDI score, although the increase in BDI scores associated with hormonal birth
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control was sufficiently close to statistical significance to suggest that honnonal birth
control might actually be associated with less improvement in BDI score (p=0.078, Table
11 row 4).

Table 11. Tests for associations between change in BDI scores and medication use (Mann-Whitney U
Tests). *denotes statistically significant difference

Taken
'M~dication Class

OTC Pain Relief
Mood Medication
Antibiotics
Birth Control
OtherOTC

.

", n"~

16
6
S
12
S

Not Taken

." Mean
-4.S6
-9.83
-8.40
-l.33
-2.60

SD

n

Mean

6.72
8.86
14.84
8.1S
3.S8

8
18
19
12
19

-4.13
-2.61
-3 .37
-7.S0
-4.89

~

.SD

P

14.22
-9.29
7.86
10.16
10.60

0.383
0.024*
0.891
0.078
0.891

Birth Control Use
Because associations with birth control bordered on statistical significance in
several results, I analyzed the BDI results by grouping the subjects into those who used
birth control versus who did not.
Birth control pills used by all participants in the study were combination
estrogen/progesterone oral contraceptive pills (OCPs) (Table 12). The specific
progesterone varied based on the subject's prescription, but all subjects' oral
contraceptives were fonnulated with ethinyl estradiol (BE), a bioactive derivative of
estradiol (E2). The majority of subjects taking OCPs were exposed to 0.030-0.03Smg of
EE with each pill.
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Table 12. Subjects using oral contraceptive pills. Prescriptions varied with regard to dose and type of
progestational compound. Subject 029's prescription contained a different formulation for each week of her
cycle.
lil Subj~ct {i\r ';'OCI»

Bfand':' :". . FQrmbhition\l~j"ii

"'I.'

.

,. '(0~~114t*~i'"

':v'\"\~:ii'~!~i

003

low ogestrel

:,~;
0.03 mg EE and 0.3 mg norgestrel

014

levora 0.15mg

0.03 mg EE and 0.15 mg levonorgestrel

015

gianvi

0.02 mg EE and 3 mg drospirenone

016

ortho tri-cyclen

0.035 mg EE and 0.18 mg norgestimate

021

sprintec

0.035 mg EE and 0.250 mg norgestimate

022

ortho tri-cyclen

0.035 mg EE and 0.18 mg norgestimate

024

levora

0.03 mg EE and 0.15 mg levonorgestrel

025

ortho tri-cyclen

0.035 mg EE and O. 18 mg norgestimate

026

sprintec

0.035 mg EE and 0.250 mg norgestimate

027

levora

0.03 mg EE and 0.15 mg levonorgestrel

029

tri -sprintec

Week 1: 0.035 mg EE and 0.18 mg

;"

norgestimate; Week 2: 0.035 mg EE and
0.215 mg norgestimate; Week 3: 0.035
mg EE and 0.25 mg norgestimate
030

unspecified

Reports on the use of OCPs and their effects on depression vary; some studies
have found that OCPs are correlated with a worsening of depressive symptoms in women
with severe peri menstrual symptoms and/or a predisposition toward major depressive
disorder [137, 138], while other studies have not confirmed this relationship. The use of
OCPs for relief of severe peri menstrual syndrome (PMS) or perimenstrual dysphoric
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disorder (PMDD) often treats only the pain and abnormal menstrual flow associated with
these disorders and not the associated affective and somatic aspects of depression [139].
Since research indicates that estrogen influences the serotonergic pathway by upregulating tryptophan restriction [123], exogenous administration oflow-dose estrogen,
such as that in an estrogen-containing OCP, may increase depressive symptoms in some
women.
This study indicated that there is a trend toward the use of OCPs and the
worsening of depressive symptoms. Subjects who took OCPs and mood medication had
significantly improved BDI scores relative to those who used OCPs but did not use mood
medication (p=0.031 , Table 13, row 5). This improvement was significant for the
affective sub scores (p=0.015, Table 13, row 3) but not in the somatic (p=0.089, Table
13, row 4). However, subjects who did not take OCPs did not have improved BDI scores
when using mood-related medication (p=0.467, Table 14, row 5). This difference
indicates that subjects who used birth control may have initially been more depressed
than those that did not use birth control (Table 11 , row 4), but the use of mood-altering
medications ameliorated these depressive symptoms.

Table 13. Tests for an association of BDI scores with mood-altering medication, among subjects who used
birth control (Mann-Whitney U tests). * denotes a statistically significant difference

Mood Meds
(n=2)

No Mood Meds
(n=10)

.'!i

Mean

"<

SD

Meant;

SD

,
to< ,

p

Initial BDI Score

21.00

14.14

8.30

9.90

0.091

Final BDI Score

8.00

9.90

9.30

6.31

0.38

Change in Affective Sub score

-5.00

2.82

0.30

1.64

0.015*

Change in Somatic Sub score

-8.50

0.71

-0.75

4.33

0.089

-13.00

4.24

1.00

6.50

0.031*

Change in Overall Score
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Table 14. Tests for an association of BDI scores with mood-altering medication, among subjects who did
not use birth control (Mann-Whitney U tests). All p-values are one-tailed.

Initial BDI Score
Final BDI Score
Change in Affective Sub score
Change in Somatic Sub score
Change in Overall Score

Mood Meds
n=4
Mean ,
SD
23.00
14.14
14.75
9.90
-2.75
2.82
-5.50
0.71
-8.25
4.24
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No Mood Meds
n=8
Mean
SD
16.25
9.90
9.30
6.31
0.30
1.64
-0.75
4.33
1.00
6.50

p
0.933
0.282
0.368
l.00
0.933

CHAPTERS

DISCUSSION AND FUTURE CONSIDERATIONS

Summary of Findings

The original goal of the study was to detelTIline if changes in depressive
symptoms were correlated with infection status, and if treatment of the infection led to an
amelioration of depressive symptoms. I had hoped to study the association of depression
with Chlamydia trachomatis but difficulties in subject recruitment led to a broadening of
scope.
The use of mood-altering medications such as fluoxetine (Prozac) and lamotrigine
(Lamictal) was positively associated with the subject's change in BDI score. These
medications are intended to alter mood symptoms and therefore this effect was not
unexpected. Though these medications are classified in different drug classes (Appendix
H), they are prescribed for the same effect -- to ameliorate depressive symptoms and
mental illness in the patient.
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The effect of birth control on increasing depressive symptoms approached
significance in this study. The uncertainty associated with this finding reflects ambiguity
about the roles of hormonal birth control in the literature. The effect of birth control,
particularly OCPs, on depressive symptoms is controversial. The results of this study
show, however, that depression in subjects taking hormonal birth control and moodaltering medications declined over the course of the study. In contrast subjects who took
mood medication but not hormonal birth control did not show such a decline.
The exogenous estrogen introduced by OCPs may be up-regulating IDO, causing
increased tryptophan restriction and therefore less serotonin synthesis. If this is the case,
medications that are prescribed to reduce the re-uptake of serotonin, and therefore
increase its availability in the synapse, may counteract the effects of estrogen in reducing
serotonin synthesis. Though a number of subjects took mood-altering medications, only
three used an SSRI, making it difficult to statistically show an association.
The decline in BDI scores during follow-up could result from a "placebo effect"
that arises from medical attention. Contact with a physician alone can be therapeutic,
thereby improving the mood of subjects [140]. Since no physician contact occurred at
the follow-up appointment, subjects that experience improved mood due to physician
contact may have increased BDI scores, and therefore worse depression symptoms,
without the physician's visit. Alternatively, anxiety about an upcoming doctor's visit and
outright iatrophobia, or fear of doctors [141], are not uncommon phenomena and can
result in some inflation of the initial BDI scores, since subjects were recruited at their
annual exam. These subjects would have improved BDI scores at the follow-up since a
doctor was not seen.
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Limitations of the Study

A variety of real and potential confounding factors limit the conclusions that can
be drawn. As the study was clinical in nature and relied heavily on self-reported data, it
was subject to the limitations of subjective clinical research. These issues, discussed in
detail below, included recruitment, compliance, the self-report nature of the BDI, and the
truthfulness of the subject. Additionally, protocol changes complicate interpretations.

Recruitment

The most critical limitation on the study was subject recruitment. Despite the
offer of compensation for their time and travel, it was difficult to identify women who
were willing to participate. Several factors may have negatively affected recruitment.
One was subject referral. The physicians and the medical assistants were responsible for
the initial mention of the study to potential subjects. This was accomplished either by
mentioning the study directly or arranging for me to speak with the potential subject
before her exam. Often no mention of the study was made during the potential subject's
appointment, in which case the opportunity to recruit was lost.
A second factor impeding subject recruitment was the subject's own hesitation to
participate in the project. The most common reason, cited through personal
communication with the subject at both CHS and the GYN/OB Foundation, was lack of
time to stay for the initial visit. Subjects also mentioned that they were unable to return
for the follow-up appointment. Since the initial visit took around 20-30 minutes total,
subjects who had to return to work, go to class, or had other time constraints felt unable
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to take the time both to consent to participate and fill out the Beck Depression Inventory.
Several subjects approached at the GYN/OB Foundation did not directly decline
participation but instead checked out and left immediately after the exam; staff speculated
that these women held some distrust of the nature of the research due to not
understanding the parameters. The medical assistants reported to me that these women
seemed confused about the project and its scope despite my explanation to them.
A substantially larger subject population would have allowed testing of the
original hypothesis that antibiotic treatment of C. trachomatis led to an improved mood.
The general tendency for mood scores to improve on follow-up visits, however, indicates
that detection of an effect of antibiotic treatment would have been more difficult than
originally anticipated; the improvement in mood among subjects treated with antibiotics
would have to be greater than the more general improvement that was documented by
this study.

Compliance
Failure to return for the follow-up visit was a major factor in subject noncompliance. Eight subjects failed to return for their follow-up visits, despite repeated
attempts to reschedule. An additional subject from the GYN/OB Foundation neglected to
return her calendar but did complete a follow-up BDI. Without both the subject's final
BDI scores and medication calendar, she was unable to be included in the final analysis.
A number of subjects failed to note all of the information requested on their
calendars. Most included the names of the medications that they were taking, but a few
named a medication class rather than the exact medication itself. The most common
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piece of information omitted, however, was the start date of menstruation. Only 16 of the
24 subjects who completed the study included this information on their calendars. Only
two subjects reported the use of depo provera, an injectable birth control that commonly
alters menstruation frequency; these two subjects were also non-compliant subjects and
were not included in the final analysis. It is unknown why these women did not complete
this portion of the study.

Self-report nature of the BDI

As the BDI is a self-reported measure of depression, it is subject to the limitations
of a subjective test [131, 142]. Although studies have indicated that it is a reliable tool in
comparison to physician diagnosis [143], subjects may gauge their symptoms differently
depending on any number of factors. The subjects may have exaggerated or minimized
their symptoms based on the perceived desire of the researcher; for example, if the
subject believed the researcher was hoping for a high score, she might be tempted to
exaggerate her symptoms in an effort to please the researcher [142]. Subjects might be
less likely to engage in such behaviors if the BDI was filled out in private or at home via
postal mail, but these options would introduce other potential confounding factors. In an
attempt to alleviate this risk, the researcher took precautions to not imply preferred results
in either direction.
The subject's current health status and daily mood changes may have also
influenced the study. If the subject was having a "bad day" on the date of either her
initial or final visit, she might be feeling more emotional, and therefore exaggerate the
results of the test. In this case, the test would be a measurement "in the moment" rather

Sl

than over the long term. The converse is true for a perceived "good day." Additionally,
the stress of the physician's office visit, any negative news administered by the physician,
or any current or ongoing health problems may influence how the subject responds on the
BDI. A recent short-term illness such as a cold or the flu may also alter the subject's
short-term mood and therefore alter her BDI score. This should be partially
accommodated for by the subject's report of her medication use on her calendar.

Truthfulness
The study is also limited by the subject's truthfulness and accuracy in reporting all
medication use on her calendar. If the subject did not know the name ofa medication
that was used, forgot to note a medication on her calendar, or labeled a medication
incorrectly, the results of the study could be altered. Additionally, if a subject was using a
medication incorrectly and was uncomfortable reporting this for fear of reprisal, her
calendar results and potentially her BDI results would be inaccurate. It was stressed to
the subjects to be as truthful, accurate, and honest as they could, and subjects were
informed that the Health Insurance Portability and Accountability Act (HIP AA) required
us to maintain confidentiality even in cases of illegal drug use. Each subject was
reminded that the only situation where confidentiality would be breached is if the subject
was an immediate danger to herself and/or others, and in this case we would only discuss
it with her physician. However, some subjects may have omitted this information despite
assurances of privacy.
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Changes in Protocol

There were changes made to the study protocol that may have had a minor effect
on the results. Subjects at GYN/OB Clinic were read their surveys, while those at CHS
were allowed to read them themselves. The decision was made to read the subjects at

GYN/OB Clinic their questions due to possible comprehension issues since we could not
be assured of the education level of the participants. However, it may have made
subjects feel less at-ease with the study personnel. At CHS, all of the subjects were in
college or graduate school, so reading comprehension was less of a concern. Though this
could have potentially influenced the results, any influence would likely be minor.

A Model for the Development of Depression

Because of the multifactorial nature of the development of mental illness, it has
historically been difficult to model the development of major depressive disorder. Many
of the variables that influence depression development also have a single or bi-directional
causal relationship on each other. For example, Kendler et al. developed two separate
models for men [144] and women [145] based on 18 risk factors, 17 of which were
shared and the single discordant factor (low parental warmth for men vs. disturbances at
home for women) was part of the same childhood risk factor category. Both models had
a relatively good fit despite their complexity, but neither model addressed how
inflammation and sex hormones might influence the incidence of an episode of major
depression. A simpler model developed by Wichers et al [146] teased out how genetic
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influences that alter vulnerability to depression can have both a direct effect on
depression development and an indirect effect by influencing negative life events, but this
model also neglected to consider an immune system component of depression or the role
of hormones. With the overall burden of depression higher for women, it is logical to
consider how physiological differences between men and women may influence the
development of depression. Because of the strong correlation of depression with sickness
behavior, a well-balanced model for the development of depression should include an
infectious/immune component as well. The development of a new model of depression
that addresses hormonal milieu and the immune/infectious component is not within the
scope of this study, but future work in this area may necessitate the construction of a new
model that addresses these factors.

Implications and Future Directions

The results of this study suggest that anti-depressive medications may be
particularly effective in ameliorating the depression associated with OCPs. This
possibility needs to be explored in detail. It is possible that subjects who experience
negative emotional side effects from birth control may benefit from use of an SSRI, or
tryptophan supplementation in their diet, because OCPs may deplete tryptophan levels.
Considering that many women who begin taking oral contraceptive pills discontinue
them within the first year of use because ofPMS-like side effects [147], preemptively
addressing the depression-like side effects could lead to a reduction in OCP
discontinuation and ultimately fewer unplanned pregnancies. Since the use of hormonal
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contraceptives is correlated with disease exacerbation, and estrogen up-regulates
tryptophan restriction, it may be prudent to determine the depression and immune status
of patients before hormonal contraception is prescribed, and to suggest non-hormonal or
low-dose alternatives for patients who may be at risk for developing depression or other
illnesses.
These results from this study must be considered preliminary because of small
sample size and uncontrolled variables. With a larger sample size and evaluation of
correlates of medication use, the validity of the hypotheses raised by this study could be
better evaluated. Blood draws to determine serum cytokine, IDO, and antibody levels
may shed more light on the relationship between depression and the immune system.
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You are invited to take part in a research study because you are a gynecology patient experiencing
normal menstrual cycles between the ages of 18 and 40 who has experienced notable shifts in
mood. The study is being conducted under the direction of Dr. Paul Ewald PhD, University of
louisville Department of Biology, Dr. Christine Cook MD, Uofl Department of Obstetrics and
Gynecology and Dr. Rich lewine PhD, Uofl Department of Psychology. Approximately 100 local
subjects will be invited to participate. Your partiCipation in this study will last for one (1) month.
Purpose

The purpose of this study is to examine changes in mood in relation to other medical factors such
as illness or infection, use of medications and hormonal cycles.
Procedures
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If you are eligible, you will be asked to answer questions to assess your mood today. You may
refuse to answer any questions that makes you uncomfortable or may make you prosecutable
under the law. At home, you will be asked to fill out a calendar every day regarding what
medications you take and when, as well as questions about your period. You will also be asked to
return in four weeks to complete the same questionnaires and tum in your calendar. At the second
visit, you will spend approximately five (5) minutes filling out the questionnaire and BDI. When you
have filled out the documents on the first day you will receive $10 compensation for your time.
Once you have filled out both documents the second time, you will be compensated an additional
$30 for your time and travel.
Potential Risks

There are no known physical risks linked with filling out these questionnaires or calendar. The only
known risk associated with this study is the psychological stress of answering questions about your
mood. In addition, you may suffer harms that we have not seen before. You may suffer harms
that are worse than we have seen.
Benefits

The possible benefits of this study include a more precisely directed treatment for your mood that
may make your symptoms better. It is possible, however that the information may not benefrt you
directly but, the information learned in this study may be helpful to others.
Alternatives

Instead of taking part in this study, you could choose to not participate and can drop out at any
time. If you deCide not to participate in this study or stop participating at any time, you will not lose
any benefits for which you may qualify.
Research Related Injury

As set forth in the Potential Risks section, there are no known risks or discomforts associated with
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completing the questionnaires or calendar in this research study. Neither the study site nor the
study doctors have set aside money to pay for treatment of any injury. You and your insurance will
be billed for the treatment of these injuries. Before you agree to take part in this research study
you should find out whether your insurance will cover an injury in this kind of research. You should
talk to the study doctor or staff about this. If you are injured, there is no money set aside for lost
wages, discomfort, disability, etc. You do not give up your legal rights by signing this form. If you
think you have a research related injury, please call Dr. Paul Ewald at (502) 852-8816.
Compensation

You will be compensated for your time, inconvenience, or expenses while you are in this study.
The total compensation is forty dollars ($40). You will receive ten dollars ($10) at enrollment with
the completion of the first set of questionnaires. You will receive thirty dollars ($30) more at your
second visit in four (4) weeks at the completion of the second set of questionnaires and turning in
your calendar.
Because you will be paid to be in this study the University of Louisville must collect your name,
address, social security number, ask you to sign a W-9 form, and keep records of how much you
are paid. You mayor may not be sent a Form 1099 by the University. This will only happen if you
are paid more than $600 in one year by the University. We are required by the Intemal Revenue
Service to collect this information and you may need to report the payment as income on your
taxes.
This information will be protected and kept secure in the same way that we protect your other
private information. If you do not agree to give us this information, we can't pay you for being in
this study. You can still be in the study even if you don't want to be paid.
Costs

If you are injured by the research, there may be additional cost for participating in the research.
Otherwise there will be no additional cost to you. However, you or your insurance company will be
billed for all office visits and procedures that are part of routine medical care. It is your
responsibility to find out what costs, if any, your insurance company will cover before taking part in
the study.
HIPAA Research Authorization
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides federal
safeguards for protected health information (PHI). Examples of PHI are your name, address, and
birth date. PHI may also include your medical history, results of health exams and lab tests, drugs
taken and results of this research study. Your PHI may not be used or shared without your
agreement, unless it meets one of the HIPAA exceptions. If you agree to take part in this research
you may be required to sign a "Research Authorization" form. This allows the use and sharing of
your PHI by those listed in the "Research Authorization.·
Confidentiality

Total privacy cannot be guaranteed. We will protect your privacy to the extent permitted by law. If
the results from this study are published, your name will not be made public.
Consent version date_ _ __
Page3of5
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The following may look at your research and medical records:
•
•
•
•
•

The sponsor and others hired by the sponsor to oversee the research
The University of Louisville Institutional Review Board, Human Subjects Protection Program
Office, Privacy OffIce and others involved in research administration at the University
People who are responsible for research and HIPAA oversight at the institutions where the
research is conducted
Govemment agencies, such as: (List all that apply)
o Office for Human Research Protections,
o OffIce of Civil Rights,
People responsible for billing, sending and receiving payments related to your participation
in the study.

Security

Your data will be kept private by being stored on a password-protected computer that is only
accessible to the investigators and study staff. Completed questionnaires will be stored in a locked
file cabinet located in the Biology Department andlor the researcher's residence.
Conflict of Interest
There are no conflicts of interest regarding your participation in this study.
Voluntary Participation

Taking part in this study is completely voluntary. You may choose not to take part at all. If you
decide not to be in this study, you won't be penalized or lose any benefits for which you qualify. If
you decide to be in this study, you may change your mind and stop taking part at any time. If you
decide to stop taking part, you won't be penalized or lose any benefits for which you qualify.
You will be told about any new information leamed during the study that could affect your decision
to continue in the study.
Termination

Your study doctor has the right to stop this study at any point. Your study doctor may take you out
of this study with or without your okay. Reasons why this may occur include: determining that you
do not suffer from shifts in mood or that you were not seen for a routine gynecological exam.
Participation in Other Research Studies

You may take part in this study if you are currently in another research study. It is important to let
your doctor know if you are in another research study.
Contact Persons

If you have any questions, concems, or complaints about the research study, please contact Dr.
Paul Ewald at (502) 852-8816 or Amber Carrier at (812) 454-4852.
Research Subjecfs Rights
Consent version date_ _ __
Page 4 of 5
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If you have any questions about your rights as a research subject, you may call the Human
Subjects Protection Program Office at (502) 852-5188. You may discuss any questions about your
rights as a research subject, in private, with a member of the Institutional Review Board (IRB). You
may also call this number if you have other questions about the research, and you cannot reach
the study doctor, or want to talk to someone else. The IRB is an independent committee made up
of people from the University community, staff of the institutions, as well as people from the
community not connected with these institutions. The IRB has reviewed this research study.
Concerns and Complaints

If you have concerns or complaints about the research or research staff and you do not wish to
give your name, you may call the to/I free number 1-877-852-1167. This is a 24 hour hot line
answered by people who do not work at the University of Louisville.
Acknowledgment and Signatures

This informed consent document is not a contract. This document tells you what will happen
during the study if you choose to take part. Your signature indicates that this study has been
explained to you, that your questions have been answered, and that you agree to take part in the
study. You are not giving up any legal rights by signing this informed consent document You will
be given a copy of this consent form to keep for your records.
Do you want your primary care physician notified that you are a subject in this study? LlYes LlNo

Printed Name of
SubjectJLegal Representative

Signature of Subject/Legal Representative

Date Signed

Printed Name of Person
Explaining Consent Form

Signature of Person Explaining
Consent Form (if other than the Investigator)

Date Signed

Printed Name of Investigator

Signature of Investigator

Date Signed

LIST OF INVESTIGATORS
Paul Ewald, PhD
Richard Lewine, PhD
Christine Cook, MD
Amber Carrier, PhC

PHONE NUMBERS
(502) 852-8816
(502) 852-3243
(502) 561-7441
(812) 454-4852

UN1VER$lTY OF LOUlSVILlE

INSTIT~UEWBOARD
DATEAPPR'D

Consent version date,_ _ __
Page !! of5
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APPENDIXB

IRB#:

AUTHORIZATION FOR USE AND DISCLOSURE OF YOUR
HEALTH INFORMATION FOR RESEARCH
I Study Title
Exploratory study on mood among gynecology patients

I

PRINCIPAL INVESTIGATOR/PROJECT DIRECTOR (PI/PO)
Name (Last Name, First Name, MI)
Email Address
Ewald Paul' Cook Christine' Lewlne Richard
Pw.ewald@louisville.edu
Mailing Address - Include University
Telephone Number
Department (if applicable)
(502) 852-8816
L5218
Pager/Cell Phone Number
Dept of Biology
UofL
Fax Number
Lou., KY 40292
Please read this form before you sign It.
In our research, we will look at and may share information about you and your health. Federal
law requires that health providers and researchers protect this Information and keep It private
(confidential). "We" or "us" in this document refers to the following places (institutions,
facilities, and practices) that are checked ("').
Affiliated Sites
[,(] University of Louisville (Do not remove this
check.)
[J Jewish HosQltal & St. Mary's Healthcare
[J
Norton Healthcare, Inc., Including Kosalr
Children's Hospital
[J University of Louisville HospltaljJ. Graham
Brown Cancer Center

Non-Affiliated Sites
Louisville Metro Public Health & Wellness

[]
[]
[]

KY Cabinet for Health & Family Services
Seven Counties Services

[J

other(s):

University of Louisville Research Foundation (ULRF) Clinical Sites
[]
[J
Children & Youth Clinic
UL Pathology Flow Cytometry Lab (BCC)
[]
[J
Dentistry Clinics (Undergraduate DMD;
UL Pathology Special Procedures Lab
Graduate, Perlo, Endo and Ortho; Oral Surgery
and GPR at ACB; Faculty Practice, Graduate
Pedodontic Clinic)
[]
[]
Family Medicine - (Newburg and Central
University Health Services (HSC and Belknap)
Station; also Geriatrics and Sports Medicine at
Central Station)
[J
[J Harambee Nurslno Center
Welsskopf Child Evaluation Center
[]
[J
Kidney Disease Program (Dialysis Unit and UL
WHAS Crusade For Children Audiology & Speech
Renal Transp.ort Lab)
Pathology Center
[J
[J Neonatal Follow Up Program
WINGS Clinic - (ACB)
Faculty Practice Group Sites
University Anesthesiology AssoCiates, PSC

[]

[]
[]

[J
[J
[]
[]

[J
[J
[]
[]

University Radiological Assodates PSC
University Physicians Associates (UPA)/ UPG Radiology, PSC
University Emeroeney Medicine Associates PSC
University Family Practice Associates PSC
University Physicians AsSOCiates (UPA1 PSC
University Medical Assodates (UMA), PSC
Associates In Dermatology, PLLC
University Neurologists PSC
Neurosurgical Institute of Kentucky, PSC

Form: Research Authorization - FINAL (Rev 02·16-09)

[J
[J
[]
[]

[J
[J
[]
[]
[]

University Pediatrics Foundation, Inc. d/b/a
University Child Health Spedallsts, Inc.- (UCHS)
University Children's Sleep Specialists LLC
University Children's Infectious Disease
Spedallsts LLC
University Children's Kidney Specialists LLC
Unlversl!y' Children's Sedation Service LLC
University Pediatric Endocrinology, LLC
Bone Marrow Transplant LLC
Neonatal AsSOCiates PSC
Pediatric & Perinatal Patholoov Associates PSC
PediatriC Cardiology Assodates, PSC
Page 1 of 4
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[,(]

[]
[]
[]

Pediatric Hematolooy/Oncology Specialists PSC
Pediatric Pulmonary Medicine PSC
University Psychiatric Foundation, Inc.

[]
[]
[]
[]
[]

Universitv GYN/OB Foundation Inc.
University OB/GYN Associates PSC
Ophthalmological Services, Inc. - Primary Eye
Clinic
Eye Specialists of Louisville PSC
Kentucky Vision Center Inc.
Shea Tillett Malkani Caborn PSC
Spine Institute PSC
Orthopedic Trauma AssOCiates, PSC

[]
[]
[]
[]
[]

[]
[]

University Patholooists PSC
Louisville Pathology Laboratory Associates Inc.

[]
[]

University
University
University
University
University
PSC
University
Other:

[]

[]

Psychiatric Services PSC
Radiotherapy Associates PSC
Surolcal Associates PSC
Pediatric Surgery Associates PSC
Cardlothoracic Surgical AssOCiates,
Urolooy. PLLC

The law allows us to look at and share your health information for research, if you agree to let
us do this and if we protect it as required.
This form explains how we will look at and share your health information, as well as, who may
see it and use your information. If you sign this form, it means you are letting us look at and
share information for research.
1.

[]
[,(]
[]
[]
[,(]
[,(]
[]
OR
[,(]
[]
[]
[,(]
[,(]
[,(]

2.

Health information about you from the items checked below may be looked at or
given out to others.
Consultation reports
[ ] Records of your operation(s)
Diaries and questionnaires
[ ] Medical progress notes
Discharge summaries
[ ] Photos, videotapes, or digital or other
images
Healthcare provider orders
[ ] Records about the study device
History and physical exams
[ ] Records about the study drug and other
drugs you may be taking
Laboratory, x-ray, and other tests
[ ] Other:
WE WILL NOT BE LOOKING AT ANY OF THE ITEMS LISTED BELOW FOR THIS STUDY.
THE INFORMATION WE MAY LOOK AT OR GATHER FOR THIS RESEARCH MAY INCLUDE:
HIV / AIDS status
Hepatitis infection
Sexually transmitted diseases
The diagnosis and treatment of a mental health condition
Other reportable infectiOUS diseases

The following people or groups may share, receive and/or look at your information:
The people and organizations listed on this form to conduct, analyze, and understand
this study;
You or your personal representative;
Others as allowed or required by law;
Government entities that have the responsibility to oversee this research;
The offices and departments responsible for oversight of research at the University of
Louisville;
Health care providers and others where you receive care during your participation in
this study;
Health care providers and others, as appropriate, for compliance oversight; and
People responsible for sending and receiving payments related to your participation in
the study.

Form: Research Authorization - FINAL (Rev 02-16-09)
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In addition, the groups checked below may share, receive and/or look at your
information:
[ 1 The sponsor of the study and the people that the sponsor may contract with for the
study. The name of the sponsor is:
[ 1 Investigators and research staff at other places that are participating in the study;
[1 An outside institutional review board (human subjects review board)
[ 1 The Data Safety Monitoring Board
[1 Other:
If you have questions about who these people or organizations are, you may ask us.
3.

While we are required to protect your health information, once any information
leaves our institutions, we cannot promise that others will keep it private
(confidential).

4.

The information we look at or give to others as part of the research will be
analyzed and further studied to answer the research questions and to make sure
that the research was done correctly.

S.

You have the following rights:
You do not have to sign this form. However, if you do not sign this form you will not be
able to take part in this research. This will not change the health care or health care
benefits you would otherwise receive.
You may cancel the permission you have given in this form at any time. This means you
can tell us to stop using and sharing your information. If you cancel your permission:
We will stop collecting information about you.
You may not withdraw information that we had before you told us to stop.
o We may already have used it or shared it.
o We may need it to complete the research.
Staff may follow-up with you if there is a medical reason to do so.

To cancel your permission, you should complete a written "Revocation of
Research Authorization" form. Please send completed form to:
Institutional Review Board
MedCenter One, Suite 200
501 E. Broadway
Louisville, KY 40202
A revocation form may be obtained from your study doctor, designated personnel or from
the Human Subjects Protections Program Office website
(http://louisville.edu/research/hymansubjects/subject-information). If you have any
questions, call the Human Subjects Protections Program Office at (502) 852-5188.

6.

The time period when information can be used or shared ends when all activities
related to this study are completed.

7.

Your access to your health information ["'] will [ ] will not be limited during this
study.

Page 3 of 4
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If you do not know what something means, you may ask us. Before you sign this, you may talk
it over with someone you trust. You will be given a copy of this form after you have signed it.

FOR ADULTS (OR MINORS) CAPABLE OF GIVING AUTHORIZATION:

Subject's Signature

Date Signed

Printed Name

FOR CHILDREN OR ADULTS NOT CAPABLE OF GIVING AUTHORIZATION:

Signature of Parent/Surrogate/
Guardian/Health Care Agent for Subject

Date Signed

Printed Name

Relationship of representative (Surrogate) to Subject:

NOTE: THE PRINCIPAL INVESTIGATOR MUST:
PROVIDE A COPY OF THE SIGNED AUTHORIZATION TO THE SUBJECT
RETAIN THE ORIGINAL SIGNED AUTHORIZATION IN THE RESEARCH RECORD
PLACE A COPY OF THE SIGNED AUTHORIZATION IN THE SUBJECT'S MEDICAL RECORD

Form: Research Authorization - FINAL (Rev 02-16-09)
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APPENDIXC

Exploratory Study on Mood among Gynecological Patients
18-40 Years-old

•

Name: _ _ _ _ _ _ _ _ _ _ _ _ date of birth: _ _ _ __

Are you here for a routine exam?

Yes/No

What was the first day of your last menstrual period: _ _ _ _ _ _ __

Did you have a pap smear and lab tests performed today?

Yes / No

Are you on any medications or have you taken any medicine in the last thirty
(30) days (including vitamins, herbal supplements, topical ointments,
suppositories)? Yes / No
Ifyes,what _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ ____

Do you have any medical conditions? Yes / No
If yes, what medical condition(s) do you have? _ _ _ _ _ __
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BDI-II
Name: _ _ _ _ _

~.

_
_ _ _ _ _ _ _ _ _ _ Marital Status: _ _ _ _ Age: _ _ _ Sex: _ _

Occupation: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Education:
Instructiolls: This questionnaire consists of 21 groups of statements. Please read each group of Statements carefully, and
then pick out the one statement in each group that best describes the way you have been feeling during the past two
weeks, lDduding today. Circle the number beside the statement you have picked. If several statements in the group
seem to apply equally well, circle the highest number for that group. Be sure that you do nut choose more than one
statement for any group, including Item 16 (Changes in Sleeping Pattern) or Item 18 (Changes in Appetite).

6. Punishment Feelings

1. Sadness

o rdo nor feel sad.
2
3

o
I

I feel sad tnIlCh of the time.
r am sad all the time.
I am so sad or unhappy that 1 can't stand it.

2

2. Pessimism
o 1 am not discouraged about my future.
I feel more disoouraged about my future than 1
nsed to be.
.
2 I do not expect things 10 work out for me.
3 I feel my future is hopeless and will only get
worse.

o

r do not feel like a failure.

2
3

I have failed more than I should bave.
As 11001< back, I see a lot offailures.
I feel I am a total failure as a person.

I
2

2

I

2

I feel1he same about myself as ever.
I bave lost confidence in myself.
I am disappointed in myself.
I dislike myself.

8, Sa if-Criticalness

o

I get as much pleasure as I ever did from Ibe
lbings I enjoy.
I don't enjoy things as much as I used to.
I get very little pleasure from lbe 1bings I used
to enjoy.
I can't get any pleasure from the things 1 used
to enjoy.

5. Guilty Feelings
o

o

I don't criticize or blame myself more than usual.
I am more critical of myself than I used to be.
I criticize myself for all of my faults.
I blame my self for everything bad lbat happens.

9. Suicidal Thoughts or Wishes

4. Loss of Pleasure
o

7. Self-Dislike

o

3. Past Failure

I don't feel I am being punished.
I feel I may be punished.
I expect to be punisbed'
I feel I am being pnnished.

I don't feel particularly guilty.
I feel guilty over many things I have done or
should have done.
I feel quite guilty most of Ibe time.
I feel guilty all of the time.

I don't bave any thougbts of!<illing myself.

r have thoughts of killing myself. but I would
not carry them out.
I would like to !<ill myself.
I would kill myself if I had the chance.

10. Crying
o

I don't cry anymore Iban I used to.
I cry more than I used to.
I cry over every little lbing.
I feel like cryiug, but I can't.

_ _ Subtotal Page 1
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17. Irritability
1".
Agitation

!

0

I am no more restless or wound up than usual.

o

I
2

I feel more restless or wound up than usual.
I am so restless or agitated that ifs hard to stay

I
2

still.
I am so restless or agitated that I have to keep
moving or doing something.

18. Changes ill Appetite

o

I have not experienced any change in my
appetite.
1. My appetite is somewhat less than usual.
Ib My appetite is somewhat greater than usual.
20 My appetite is much less than before.
~..~l\{y appetite is much greater than usual.
3. I have no appetite at alL
3b I crave food all the time.

12. loss Of Interest

o

2
3

I have not lost interest in other people or
activities.
I am less interested in other people or things
than before.
I have lost most of my interest in other people
or things.
It's hard to get interested in anything.

13_ Indecislvaness

o

19. Concentralion DiffiCulty

I make decisions about as well as ever.
I find it more difficult to make decisions than

o
I

usual.
2

2

I have much greater difficulty in malting
decisions than I used to.
I have trouble making any decisions.

2

o

I don't consider myself as worthwhile and useful
as I used to.
I feel more worthless as compared to other
people.
I feel utterly worthless.

15. Loss 01 Energy

o
1
2

1 can concentrate as well as ever.
I can't concentrate as well as usual.
It's hard to keep my mind on anything for
very long.
I find I can't concentrate on anything.

20. Tiredness or Fatigue

14. Worthlessness
o I do not feel I am worthless.
1

I am no more irritable than usual.
I am more irritable than usUa!.
I am much more irritable than usual.
I am irritable all the time.

I am no more tired or fatigued than usual.
I get more tired or fatigUed more easily than
usual.
I am too tired or fatigued to do a lot of the things
I llsed to do.
I am too tired or fatigued to do most of the
things I used to do.

21. loss of Interest in Sex

I have as much energy as ever.
I have less energy than I used to have.
I don't have enough energy to do very much.
I don't have enough energy to do anything.

o

I have not noticed any recent change in my

interest in sex.
I am less interested in sex than I used to be.

2
3

I am much less interested in sex now.
I have lost interest in sex completely.

16. Changes in Sleeping Panern

o
la

lb

2.
2b

3.
3b

I have not experienced any change in my
sleeping pattern.
I sleep somewhat more than usual.
I sleep somewhat less than usual.
I sleep a lot more than usual.
I sleep a lot less than usual.
I sleep most of the day.
I wake up 1-2 hours early and can't get back
to sleep.

w

o

"«'"
~

;:

___ Subtotal Page 2
_ _ Subtotal Page 1
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Attachment C

University of Louisville
Human Subject Receipt for Compensation

(please keep this portion ofform in department with all study records)
Participant Name
Participant Code
Study Name
Amount of Compensation
Date of Compensation ~~~~~~~~~~~~~~~~~~~~_
Signature ofParticipant~~~~~~~~~~~~~~~~~~_.

(Please return this portion ofform to Controller's Office along with petty cash
reconcilement or payment request.)

Participant Code
Amount of Compensation _~_ _~_._~~~_~~~_~~~_~_
Date of Compensation _ _~~___~~_ _~~_ _~~_ _~~~~_
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APPENDIXF
IRS NUMBER 09 .0226

PLEASE WRITE DOWN WHAT MEDICINES YOU TAKE AND WHEN YOU TAKE THEM .
ALSO, MARK WHEN YOU START YOUR PERIOD . PLEASE FILL THIS OUT EVERYDAY
TO MAKE SURE IT IS CORRECT . PLEASE NOTE WHEN YOU ARE SCHEDULED TO RETURN TO FILL OUT THE SECOND PAIR OF QUESTIONNAIRES AND RECEIVE THE
REST OF YOUR COMPENSATION.

6

7

8

9

10

II

16

17

18

80

81

12

20

29
,

~',

For questions, pleose contoct Corrie Doyle ot 502-489-1904 or Amber Corrier ot 812-454-4852
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STUDY AD:

Female? Between 18 and 40? Is it time for a Check-up?
If you're female and it's time for your annual check-up, you may be eligible to participate
in a simple research study on mood. Eligible patients will fill out two short
questionnaires on their mood and take home a calendar to track medication use. They
will then be asked to return the calendar in a month and repeat the questionnaires. If you
qualify, you will be compensated $10 at the first visit and $30 at the second for your time
and participation. For more information about the study, please contact Amber N. Carrier
at amber.carrier@louisville.edu

STUDY EMAIL:
Thank you for your inquiry about the study on mood in gynecology patients.
To be eligible for the study, patients must be female, between the ages of 18 and 40, and
present for an exam at Campus Health Services, Belknap Campus. You may be excluded
from the study if you are not having certain tests done at your annual exam.
Additionally, certain chronic diseases that affect the menstrual cycle may exclude you
from the study (birth control is okay), but many other chronic conditions are okay. Your
provider will determine your eligibility at your appointment.
Our goal is to correlate health status, the menstrual cycle, and medication use with
changes in mood over the course of the month. Eligible patients are recruited at the time
of their annual exam. They are asked to fill out a couple of short questionnaires
concerning their mood. They then take home a calendar on which they mark the days
that they take certain medicines and when they start their period. Mter about a month,
the patient is asked to return to fill out the questionnaires again. Each visit is brief
(approximately 20 minutes at the first one, and 5-10 minutes at the second one). To
compensate each patient for her time and participation, she will receive $10 at the first
visit and $30 at the follow-up a month later, for a total of $40 for completing the study.
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Please note that we do not cover the medical costs associated with your exam and any
follow-up treatment. Please contact your healthcare insurer to determine if your health
care coverage includes the cost of an annual exam.
If you would like to schedule an appointment for your exam, please contact Campus
Health Services, Belknap Campus at (502) 852-6479. At your exam, your provider will
confirm if you are eligible to enroll in the study if you choose. The best times to
schedule your appointment in order to ensure that I will be present and able to enroll you
are on Monday, Wednesday, and Friday all day and Tuesday and Thursday afternoon.
Other times I cannot guarantee that I will be available. Please contact me regarding
Wednesday availability if that is when your exam is scheduled. If you cannot schedule
an appointment at a time that I will be present, contact me and we can work out a time to
enroll you in the study within a few days of your exam.
If you have any further questions please feel free to contact me. I appreciate your
interest!

Sincerely,
Amber N. Carrier
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APPENDIXH
MEDICATIONS USED IN THE FINAL ANAL YSIS
Drug names were taken from the National Library of Medicine and from
Chemfinder. com

Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:

Acetaminophen
N -acetyl-para-aminophenol
Tylenol, Lortab, Midol
relieves pain from headaches, menstrual periods, muscle
aches, colds and sore throats, and to reduce fever
analgesic, antipyretic

Medication:

Amitriptyline

IUPACName:

3-(1O,11-dihydro-SH-dibenzo[a,d]cycloheptene-Sylidene)-N,N-dimethylpropan-1-amine
Elavil, Endep
anti-depressant, migraine prevention
tricyclic antidepressant

Ingredient of:
Common Use:
Drug Class:
Medication:
IUPAC Name:

Amoxicillin
(2S,SR,6R)- 6-{[(2R)-2-amino- 2-(4-hydroxyphenyl)acetyl]amino}- 3,3-dimethyl- 7-oxo- 4-thia- 1azabicyclo[3.2.0]heptane- 2-carboxylic acid

Ingredient of:
Common Use:

Amoxil, Trimox, Augmentin, Amoclan
treats bacterial infections of respiratory tract, some STIs,
urinary tract infections, and ear/nose/throat infections
penicillin-like antibiotic

Drug Class:
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Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:

Medication:
IUPAC Name:

Aspirin
acetylsalicylic acid
Aspirin, Excedrin
used to relieve swelling and pain, reduce fever, thin
blood
salicylate

Drug Class:

Azithromycin
(2R,3S,4R,5R,8R, lOR, 11R, 12S, 13 S,14R)-2-ethyl3,4, 1O-trihydroxy-3,5,6,8, 10,12, 14-heptamethyl-15-oxo11-{[3,4,6-trideoxy-3-(dimethylamino)-~-D-xylo- ]oxy}1-oxa-6-azacyclopentadec-13-yl 2,6-dideoxy-3-Cmethyl-3-0-methyl-a-L-ribo-hexopyranoside
Zithromax, Zmax
treats bacterial infections of the lungs, reproductive tract,
ears, skin, and throat
macrolide antibiotic

Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:

Bupropion
(±)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one
Wellbutrin, Zyban
anti-depressant, SAD treatment, anti-smoking
atypical antidepressant

Medication:
IUPACName:

Clindamycin
methyI7-chloro-6,7,8-trideoxy-6-{[(4R)-1-methyl-4propyl-L-prolyl ]amino }-l-thio-L-threo-a-D-galactooctopyranosi de

Ingredient of:
Common Use:

Cleocin
treats bacterial infections of the lungs, skin, blood,
internal organs, and female reproductive tract
lincomycin antibiotic

Ingredient of:
Common Use:

Drug Class:
Medication:
IUPACName:
Ingredient of:
Common Use:

Drug Class:

Diphenylhydramine
2-(di pheny lmethoxy)-N,N-dimethy Iethanamine
Benadryl, Sominex, Theratlu, Triaminic, PM variations
of OTC pain relievers such as Advil and Tylenol
relieves eye irritation, sneezing, runny nose, and allergy
Also used to treat motion sicknes and
.side effects.
.
Insomma
antihistamine
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Medication:
IUPACName:

Doxycycline
(4S,4aR,5S,5aR,6R, 12aS)-4-(dimethylamino)3,5,10,12, 12a-pentahydroxy- 6-methyl- 1,11-dioxo1,4,4a,5,5a,6,11,12a-octahydrotetracene- 2-carboxamide

Ingredient of:
Common Use:

Vibramycin, Periostat
treats bacterial infections of respiratory tract, skin,
genital, and urinary systems; can also be used to prevent
malaria

Drug Class:

tetracycline antibiotic

Medication:
IUPACName:

Drug Class:

Duloxetine
(+)-(S)-N -Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2yl)propan-1-amine
Cymbalta
anti-depressant, GAD, pain due to diabetic neuropathy
and fibromyalgia
SNRI

Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:

Ethinyl estradiol *
19-Nor-17a-pregna-1,3,5(1O)-trien-20-yne-3,17-diol
Present in almost all oral contraceptives, see below
Prevents ovulation
synthetic bioactive estradiol derivative

Ingredient of:
Common Use:

*ethinylestradiol is the estrogen component of most combination oral contraceptive pills
(OCPs) on the market, and all of the ones taken by participants in this study.

Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:
Medication:
IUPAC Name:
Ingredient of:
Common Use:

Fluoxetine
N-methyl-3-phenyl-3[ 4trifluoromethyl )phenoxy ]propan-1-amine
Prozac, Sarafem
anti-depressant, anti-anxiety (as Prozac), PMDD (as
Sarafem)
SSRI

Drug Class:

Ibuprofen
iso-butyl-propanoic-phenolic acid
Advil, Motrin, Midol
pain relief, reduce swelling and tenderness,
dysmenorrhea
NSAID

Medication:
IUPAC Name:

Lamotrigine
6-(2,3-dichlorophenyl)-1 ,2, 4-triazine-3, 5-diamine
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Ingredient of:
Common Use:
Drug Class:

Lamictal
anticonvulsant (for epilepsy), bipolar I disorder
anticonvulsant

Medication:
IUPAC Name:
Ingredient of:
Common Use:

Metronidazole
2-(2-methyl-5-nitro-lH-imidazol-l-yl)ethanol
Flagyl, Prostat
eliminates infections of reproductive tract,
gastrointestinal tract, and skin
antibiotic, amebicide, anti protozoal

Drug Class:
Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:
Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:
Medication:
IUPACName:
Ingredient of:
Common Use:
Drug Class:

Sertraline
(1 S,4S)-4-(3,4-dichlorophenyl)-N-methyl-l ,2,3,4tetrahydronaphthalen-l-amine
Zoloft
anti-depressant, panic attacks, PTSD, social anxiety,
OCD,PMDD
SSRI
Trazadone
2-{3-[4-(3-chlorophenyl)piperazin-lyl]propyl} [1 ,2,4]triazolo[4,3-a]pyridin-3(2H)-one
Desyrel,Oleptro
anti -depressant
serotonin modulator/SARI
Zolpidem
N,N-dimethyl-2-(6-methyl-2-p-tolylimidazo[1,2a]pyridin-3-yl)acetamide
Ambien
insomnia
sedative-hypnotic
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Conferences Attended
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